Penile curvature improvement in Peyronie's disease assessed in post hoc analysis of IMPRESS trials

Video

“The goal of this study was to look at that original phase 3 trial data [from 2013] and see if we could identify how much change in curvature patients were achieving with each of those 2 injections,” says Matthew J. Ziegelmann, MD.

In this video, Matthew J. Ziegelmann, MD, discusses the background of the study, “Collagenase clostridium histolyticum treatment for Peyronie’s disease: analysis of outcomes and cumulative benefits after each injection cycle,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Ziegelmann is a urologist at the Mayo Clinic, Rochester, Minnesota.

Related Videos
Dr. Landon Trost in an interview with Urology Times
Bogdana Schmidt, MD, MPH, answers a question during a Zoom video interview
3d rendered illustration of kidney cancer | Image Credit: © SciePro - stock.adobe.com
Bottle of white pills | Image Credit: © leighannef - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.